WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005016371) IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/016371    International Application No.:    PCT/US2004/021618
Publication Date: 24.02.2005 International Filing Date: 06.07.2004
IPC:
A61K 38/00 (2006.01), C07K 14/565 (2006.01)
Applicants: SCHERING AKTIENGESELLSCHAFT [DE/DE]; Müllerstr. 178, D-13342 Berlin (DE) (For All Designated States Except US).
NESTAAS, Eirik [NO/US]; (US) (For US Only).
PUNGOR, Erno [US/US]; (US) (For US Only)
Inventors: NESTAAS, Eirik; (US).
PUNGOR, Erno; (US)
Agent: GIL, Anna; Berlex Biosciences, 2600 Hilltop Drive, P.O. Box 4099, Richmond, CA 94804 (US)
Priority Data:
60/486,657 11.07.2003 US
Title (EN) IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES
(FR) POLYPEPTIDES DE L'INTERFERON-BETA-1B HUMAINS RECOMBINANTS AMELIORES
Abstract: front page image
(EN)The present invention relates to recombinant human interferon-beta-1b (“IFN-beta-1b”) polypeptides, or fragments analogs, derivatives, or variants thereof, having an improved specific activity. The present invention also relates to pharmaceutical compositions comprising such IFN-beta-1b polypeptides. or fragments, analogs, derivatives, or variants therof, useful for treating multiples sclerosis. The present invention further relates to methods of producing such IFN-beta-1b compositions.
(FR)La présente invention a trait à des polypeptides de l'interféron-bêta-1b ( IFN-$g(b)-1b ) humains recombinants, ou leurs fragments, analogues, dérivés, ou variants, présentant une activité spécifique améliorée. La présente invention a également trait à des compositions pharmaceutiques comportant de tels polypeptides de IFN-$g(b)-1b, ou leurs fragments, analogues, dérivés, ou variants, utiles pour le traitement de la sclérose en plaques. La présente invention a trait en outre à des procédés de production de telles compositions de IFN-$g(b)-1b.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)